Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 21, 2016. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Date | Instrument | Price (USD) | Volume (ADSs) | Transaction Type |
|---|---|---|---|---|
| 2016-10-20 | American Depositary Shares (ADSs) | $41.4815 | 10.943 | Acquisition (Dividend Re-investment) |
| 2016-10-20 | American Depositary Shares (ADSs) | $41.4815 | 1,196.207 | Acquisition (Dividend Re-investment) |
| 2016-10-20 | American Depositary Shares (ADSs) | $41.4815 | 26.393 | Acquisition (Dividend Re-investment) |
Material Changes
The filing does not report material changes to the company's financial position or operations. It reports routine acquisitions of ADSs by specific individuals following the re-investment of dividends paid to shareholders on October 13, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific share purchases executed on the New York Stock Exchange (NYSE).
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ADSs resulting from dividend re-investment plans, not open market purchases.
- Participants: Transactions involved Dr. M M Slaoui (Chairman, Global Vaccines), Mr. D E Troy (SVP & General Counsel), and Dr. K Slaoui (PCA of Dr. M M Slaoui).
- Execution Details: All transactions occurred on October 20, 2016, at a uniform price of $41.4815 per ADS.
- Scope: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.